Differential regulation of progranulin derived granulin peptides

Tingting Zhang, Huan Du, Mariela Nunez Santos, Xiaochun Wu, Mitchell D. Pagan, Lianne Jillian Trigiani, Nozomi Nishimura, Thomas Reinheckel and Fenghua Hu

Abstract

Background: Haploinsufficiency of progranulin (PGRN) is a leading cause of frontotemporal lobar degeneration (FTLD). PGRN is comprised of 7.5 granulin repeats and is processed into individual granulin peptides in the lysosome. However, very little is known about the levels and regulations of individual granulin peptides due to the lack of specific antibodies.

Results: Here we report the generation and characterization of antibodies specific to each granulin peptide. We found that the levels of granulins C, E and F are regulated differently compared to granulins A and B in various tissues. The levels of PGRN and granulin peptides vary in different brain regions and the ratio between granulins and PGRN is highest in the cortical region in the adult male mouse brain. Granulin-A is localized in the lysosome in both neurons and microglia and its levels in microglia increase under pathological conditions. Interestingly, the levels of granulin A in microglia change correspondingly with PGRN in response to stroke but not demyelination. Furthermore, deficiency of lysosomal proteases and the PGRN binding partner prosaposin leads to alterations in the ratios between individual granulin peptides. Granulins B, C and E are heavily glycosylated and the glycosylation patterns can be regulated.

Conclusion: Our results support that the levels of individual granulin peptides are differentially regulated under physiological and pathological conditions and provide novel insights into how granulin peptides function in the lysosome.

Keywords: Frontotemporal lobar degeneration (FTLD), Progranulin (PGRN), Granulin, Cathepsin, Glycosylation, Lysosome

Background

Progranulin (PGRN) protein, encoded by the granulin (GRN) gene, has been implicated in several neurodegenerative diseases [1, 2]. Haplo-insufficiency of the protein, due to heterozygous mutations in the GRN gene, is a leading cause of frontotemporal lobar degeneration with TDP-43 aggregates (FTLD-TDP) [3–5]. Homozygous PGRN mutations result in neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disorder [6, 7]. PGRN is known as a secreted glycoprotein of 7.5 granulin repeats [1, 2, 8]. However, accumulating evidence has suggested a critical role of PGRN in the lysosome [8, 9]. PGRN deficiency has been shown to result in lysosome abnormalities with aging [10, 11]. At the molecular and cellular level, PGRN is a lysosome resident protein [12] and GRN is transcriptionally co-regulated with many essential lysosomal genes by the transcriptional factor TFEB [13, 14]. PGRN interacts with another lysosomal protein prosaposin (PSAP) to facilitate each other’s lysosomal trafficking [12, 15, 16]. Within the lysosome, PGRN has been shown to get processed to granulin peptides by cathepsins [17–19]. These granulin peptides have been proposed to possess unique biological activities, in a way similar to the saposin peptides derived from PSAP,

* Correspondence: fh87@cornell.edu
1Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, 345 Weill Hall, Ithaca, NY 14853, USA
Full list of author information is available at the end of the article

© The Author(s). 2022 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
which function as activators for enzymes involved in glycosphingolipid degradation [20]. In line with this, PGRN and granulin peptides have been shown to regulate the activities of several lysosome enzymes, including cathepsin D [21–24] and glucocerebrosidase [25–27]. Despite these studies, very little is known about how granulin peptides are regulated in the lysosome due to the lack of specific antibodies to each individual peptide.

Results

Generation of antibodies to each individual granulin peptide

To generate antibodies specific to each granulin peptide, we purified recombinant GST tagged mouse granulin peptides from bacteria (Table S1). These proteins were then used to immunize rabbits to generate polyclonal antibodies. To test the specificity of these antibodies toward each individual granulin peptide, we expressed individual mouse granulin peptides in HEK293T cells with an N-terminal signal sequence followed by a GFP tag. HEK293T lysates containing GFP tagged granulins were then used in western blot analysis to determine the specificity of the antibodies against each individual granulin peptide. All the granulin antibodies specifically recognized their respective granulin peptide, except the granulin B antibody, which exhibits weak cross-reactivities with granulin C (Fig. 1a).

Next, we determined whether these antibodies could detect endogenous granulin peptide using liver lysates from adult WT and Grn−/− mice. Specific signals around 10 kDa were successfully detected in the WT lysates but not in the Grn−/− samples with granulin A, B, C, E, and F antibodies (Fig. 1b). Unfortunately, granulin D and G antibodies cannot detect endogenous granulin peptides, although they recognize overexpressed granulin peptides efficiently. Thus, we focused our effort on granulins A, B, C, E, and F for the current study.

Variation in the levels of granulin peptides in different tissues

To determine whether the levels of granulin peptides vary from each other, first, we analyzed the levels of each granulin peptide in different tissues using western blots (Fig. 1b, c). We found that PGRN is highly expressed in the liver, spleen, lung and kidney (Fig. 1b, c). Using the commercial PGRN antibody which preferentially recognizes granulins B, C and F (Fig. S1), a corresponding enrichment of granulins is detected in the liver, spleen and kidney, but not in the lung (Fig. 1b, c). Using antibodies against individual granulins, relatively high levels of granulins A and B in the liver, spleen and kidney but not in the lung were also observed (Fig. 1b, Fig. S2), indicating that PGRN processing or the stability of granulins A and B are different in the lung versus spleen and kidney.

Interestingly, while the levels of granulins C, E, and F are also high in the liver and spleen and low in the lung, their levels are relatively low in the kidney, as shown by a significant decrease in the ratio between granulins C/E/F and granulin A in the kidney compared to that in the liver and spleen (Fig. 1b and d). This suggests that the levels of granulin peptides could differ from each other although they are derived from the same precursor. This could be due to differential processing or differences in their stability within the lysosome.

Glycosylation of granulins B, C, and E

PGRN is predicted to contain 5 N-glycosylation sites with granulin B, C and E each harboring one glycosylation site. Additionally, glycosylation sites in granulins C and E have been mapped by mass spectrometry analysis [28]. Glycosylation is known to play an important role in protein folding and stability as well as protein-protein interaction and signal transduction [29]. In our western blot analysis, two distinct bands have been observed for granulin B, C and E at endogenous levels (Fig. 1b). We speculated that these two bands observed for granulins B, C and E could be peptides with different degrees of glycosylation. To test this, we immunoprecipitated granulin B, C and E peptides with their corresponding antibodies and treated the immunoprecipitates with PNGase F to remove N-glycans. The two bands collapsed to a single band with the lower molecular weight with PNGase F treatment, confirming that granulin B, C and E have two different glycosylated forms (Fig. 1e). More interestingly, the pattern of glycosylation for granulin B and C differs in the spleen lysates versus liver lysates (Fig. 1b,f). In both cases, an increased level of the highly glycosylated form was observed in the spleen compared to the liver, especially for granulin C (Fig. 1b, f).

Variations in the levels of PGRN and granulin peptides in different brain regions

Since PGRN is expressed by both neurons and microglia, we wonder if there is a difference in PGRN processing in neuron and microglia. We found that the levels of both PGRN and granulin peptides are much higher in microglia compared to neurons and the ratio of total GRNs to full-length PGRN is 2–3 fold higher in microglia (Fig. 2a).

PGRN is broadly distributed in different brain regions and the spinal cord [30, 31]. Thus, it will be interesting to examine the distribution of granulin peptides in different brain regions. Since granulins A and C show differential regulation and our antibodies against granulins A and C can reliably detect these peptides in the brain lysates, we compared the levels of PGRN and granulins A and C in different regions of male and female mice using western blot analysis (Fig. 2b). In male mice, the
Fig. 1  (See legend on next page.)

(a) GFP-Granulin Construct

(b) $Grn^{-}$  WT

| kDa | Liver | Spleen | Lung | Kidney | Heart | Brain |
|-----|-------|--------|------|--------|-------|-------|
| 75  | PGRN  | GRNs   | PGRN | GRNs   | PGRN  | GRNs  |
| 50  | GRN-A | GRNs   | GRN-A| GRNs   | GRN-A | GRNs  |
| 10  | GRN-B | GRNs   | GRN-B| GRNs   | GRN-B | GRNs  |
| 10  | GRN-C | GRNs   | GRN-C| GRNs   | GRN-C | GRNs  |
| 10  | GRN-D | GRNs   | GRN-D| GRNs   | GRN-D | GRNs  |
| 10  | GRN-E | GRNs   | GRN-E| GRNs   | GRN-E | GRNs  |
| 10  | GRN-F | GRNs   | GRN-F| GRNs   | GRN-F | GRNs  |
| 10  | GAPDH |        |      |        |       |       |

(c) PGRN levels

(d) GRNs/PGRN

(e) GRNs: B/A

(f) GRN-C (Top)
Fig. 1 Characterization of granulin antibodies and analysis of granulin levels in tissue lysates. a HEK293T lysates containing GFP or GFP tagged mouse granulins were probed with antibodies against each individual granulin peptide as indicated. Diagram of PGRN structure was shown at the top. b Western blot analysis of different tissues lysates from 4 to 5 months old WT and Grn−/− mice with antibodies against each individual granulin, granulin A (GRN-A), granulin B (GRN-B), granulin C (GRN-C), granulin E (GRN-E) and granulin F (GRN-F) as indicated. Full length PGRN and total PGRN-derived granulins (GRNs) were detected by commercial sheep anti-mouse PGRN antibodies (R&D). Mixed male and female mice were used for this analysis. c Quantification of experiment in (b). The ratio between PGRN and GAPDH; granulins and GAPDH and between granulins and full-length PGRN was quantified and normalized to that in the liver sample on the same gel (set as 1). Data presented as mean ± SEM. n = 3. *, p < 0.05, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001, unpaired two-tailed Student’s t-test. d Quantification of the ratios between granulins B/C/E/F and granulin A. The band intensities of different granulins were measured and normalized to GAPDH. The ratios between granulins B/C/E/F and granulin A were calculated and normalized to the lung sample on the same gel (set as 1). Data presented as mean ± SEM. The ratio of GRN-C (p = 0.04), GRN-E (p = 0.0057), GRN-F (p = 0.0006), but not GRN-B (p = 0.4586) versus GRN-A is significantly lower in kidney than that in lung. *, p < 0.05, **, p < 0.01, ***, p < 0.001, unpaired two-tailed Student’s t-test. e Granulin B, C, and E are glycosylated. Spleen or liver lysates from WT mice were immunoprecipitated using anti-granulin B, C, or E antibodies and the immunoprecipitates were treated with PNGase F. f Quantification of two differentially glycosylated forms of granulin C for experiments in (b). The ratio between top or bottom bands of granulin C and GAPDH in liver and spleen lysates was quantified and normalized to their levels in the lung. Data presented as mean ± SEM. n = 4. Top bands (p = 0.0023), bottom bands (p = 0.04), *, p < 0.05, **, p < 0.01, unpaired two-tailed Student’s t-test.

Fig. 2 Analysis of PGRN and granulin levels in brain regions and spinal cord. a Western blot analysis of primary cortical neuron (DIV14) and microglia lysates using sheep anti-PGRN antibodies. n = 4. Data presented as mean ± SEM. *, p < 0.05, unpaired two-tailed Student’s t-test. b Western blot analysis of tissue lysates from 4.5 to 5 months old male WT mice with antibodies against full-length of PGRN and individual granulin A and C as indicated. CX = cortex, Hp = hippocampus, CC = corpus callosum, Tha = thalamus, Cb = cerebellum, BS = brain stem, SC = spinal cord. c Quantification of experiment in (b). The ratio of each granulin peptide to full-length PGRN was quantified and normalized to the value of spinal cord samples on the same gel (set as 1). n = 3–5. Data presented as mean ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001, unpaired two-tailed Student’s t-test.
levels of full-length PGRN are highest in the hippocampus, corpus callosum, and thalamus, as compared to other regions (Fig. 2b and c). The levels of granulins detected with commercial anti-PGRN antibodies (Fig. S1) and the levels of granulin A and C are also high in the hippocampus and corpus callosum lysates, but relatively lower in the thalamus. In addition, although the levels of full-length PGRN are low in the cortex, the levels of granulins A and C are highest in the cortex (Fig. 2a and b). These results indicate that the levels of both PGRN and granulin peptides vary in different brain regions. This could be caused by differences in microglial density or differences in PGRN expression and processing/stability of granulin peptides in different types of neurons. However, we were unable to obtain consistent results from female mice. In females, both the levels of full-length PGRN and the ratio between individual granulins and PGRN show a high degree of variability from mouse to mouse (Fig. S3). The variability in females could be caused by changes in estrogen levels during the estrous cycle, since PGRN gene expression is known to be regulated by estrogen [30–33]. The levels of PGRN and granulins as well as the GRN/PGRN ratio can be examined at the different stages of the estrous cycle in mice to test the effect of fluctuations in estrogen and other hormones on PGRN levels and processing.

**Granulin A is localized to the lysosome in both neurons and microglia**

In addition to western blot analysis, it will be important to examine the levels and localization of individual granulins in different cell types using immuno-staining. To this end, we have optimized conditions to detect mouse granulin A in mouse brain sections by pre-incubating the antibodies with brain sections from PGRN deficient mice to get rid of non-specific signals. We have detected specific signals for granulin-A in the lysosome in both neurons and microglia, as shown by colocalization with LAMP1 (Fig. 3a). Since PGRN is known to get upregulated in microglia in many pathological conditions [8], we examined granulin-A levels in microglia upon stroke and cuprizone-induced demyelination. Increased levels of granulin A were detected in microglia after stroke (Fig. 3b, d), and granulin-A signals overlapped with signals detected by the commercial anti-PGRN antibodies and anti-LAMP1 antibodies (Fig. 3c), indicating increased levels of lysosomal granulin-A upon microglial activation in response to stroke. Interestingly, only a very modest increase of GRN-A levels was detected in microglia in the corpus callosum region in response to demyelination, although there is a significant increase in PGRN levels in microglia (Fig. 3e-g). These indicated that PGRN processing or stability of granulin A might be regulated differently in microglia with different activation states.

**Regulation of PGRN processing and granulin levels by lysosomal proteases**

Lysosomal proteases, such as cathepsins, have been shown to play a role in PGRN processing. The cysteine protease, cathepsin L, was shown to cleave PGRN to granulin peptides efficiently in vitro [17–19]. However, how lysosomal proteases regulate PGRN cleavage in vivo remains unclear. Using the granulin-specific antibodies, we analyzed the levels of each granulin peptide in the cortex of mice deficient in individual lysosomal proteases, including cathepsin B, D, L, K, and Z (Fig. 4a, b, c, Table S2). Ablation of most of these cathepsins individually does not seem to have a significant effect on the levels of full-length PGRN and total granulins, except cathepsin B and cathepsin D. The levels of both PGRN and granulin peptides are significantly upregulated in Ctsd−/− cortical lysates (Fig. 3b), partly due to transcriptional up-regulation as reported previously [32]. The ratio of granulins A, B, C, but not granulin F, to full-length PGRN is decreased in the Ctsd−/− lysates, suggesting that ablation of cathepsin D affects PGRN processing or the stability of a subset of granulins (Fig. 4b). Interestingly, a significant increase in the levels of the heavily glycosylated form of granulin C was observed in Ctsd−/− lysates (Fig. 4b), suggesting possible dysfunction of lysosomal glycosidases in response to cathepsin D loss. Although cathepsin B deficiency does not have any obvious effect on the levels of PGRN, it leads to a significant increase in the levels of granulin A and B without any obvious effects on granulin C and F (Fig. 4a), suggesting that cathepsin B might specifically regulate the generation or stability of granulin A and B in the lysosome. Despite results from in vitro studies supporting an important role of cathepsin L in PGRN processing [17–19], ablation of cathepsin L does not have any obvious effect on the levels of PGRN and granulin peptides in the brain (Fig. 4c). Cathepsins B and L are known to have overlapping functions. In cortical lysates from cathepsin B and L double knockout (Ctsb−/− Ctsl−/−) mice, levels of full-length PGRN are significantly increased (Fig. 4d), possibly due to transcriptional upregulation caused by severe lysosomal abnormalities in these mice [33, 34]. However, the ratio between individual granulin peptides to full-length PGRN is not altered in Ctsb−/− Ctsl−/− brain lysates, indicating that none of these two cysteine proteases is essential for PGRN processing in vivo. It should be noted that the levels of other lysosomal proteases are likely to be changed upon the loss of one or more proteases [35]. Thus, other proteases may get upregulated to process PGRN in the absence of cathepsins B and L. Heavily glycosylated form of granulin C accumulates in Ctsb−/− Ctsl−/− cortical lysates similar to that in Ctsd−/− mice, indicating changes in the activities of lysosomal glycosidases upon lysosomal dysfunction.
Interestingly, the glycosylation pattern of granulin B does not appear to be affected in Ctsb<sup>−/−</sup> Ctsl<sup>−/−</sup> cortical lysates, suggesting the glycosylation of granulin B and C are subject to different regulations.

**Regulation of PGRN processing and granulin levels by prosaposin (PSAP)**

PGRN interacts with another lysosomal protein prosaposin (PSAP) to facilitate each other’s lysosomal trafficking [12, 15, 16]. Within the lysosome, PGRN and PSAP get processed to individual granulins [17–19] or saposins [20], respectively. However, it remains unknown whether the interaction between PGRN and PSAP influences each other’s processing. To determine the role of PSAP on PGRN processing, we examined the levels of PGRN and granulin peptides in cortical lysates from Psap<sup>−/−</sup> mice. Due to early lethality and lysosomal abnormalities in Psap<sup>−/−</sup> mice [20], there is a significant increase in the...
Fig. 4 (See legend on next page.)
levels of both PGRN and granulin peptides because of transcriptional responses. However, the ratio of granulin peptides to full-length PGRN is significantly decreased (Fig. 5a, b), consistent with the fact that PSAP is required for efficient PGRN lysosomal delivery [12, 15, 16]. Interestingly, the fold of increase in granulin C and F levels are much more than that in granulins A and B levels in Psap−/− mice (Fig. 5b). While granulin F levels are increased proportionally to full length PGRN and the levels of granulin C are also drastically increased, there are very little changes in the levels of granulin A and B, which is reflected in the increased ratio of granulin C to A and of granulin F to A (Fig. 5b). These results further support that the levels of individual granulin peptides can be differentially regulated. In addition, there is a significant increase in the levels of hyper-glycosylated forms of both granulin B and C in the cortical lysates from Psap−/− mice (Fig. 5a), supporting that glycosylation of granulin B and C are subject to regulation in pathological conditions.

**Discussion**

PGRN shares many similarities with its binding partner and travel companion prosaposin (PSAP). By forming a complex, these two proteins facilitate each other's lysosomal trafficking [12, 15, 16]. In addition, when reaching the lysosome, PGRN and PSAP are processed into granulins and saposins, respectively, through the action of lysosomal proteases [9]. Saposins are key regulators of enzymes involved in the glycosphingolipid degradation
pathway [20]. Interestingly, although derived from the same precursor, individual saposins are known to be regulated differently in the lysosome. For example, saposin A and D are the main protein components of lipofuscin found in many lysosomal storage diseases [36], indicating that saposin A and D have distinct biochemical properties in the lysosome compared to saposin B and C. However, not much is known about the function and regulation of granulin peptides in the lysosome. Since granulin peptides are likely to be the functional units of PGRN within the lysosome and PGRN haploinsufficiency in FTLD is known to cause haploinsufficiency of granulin peptides [17], it is critical for us to understand how the levels of individual granulins are regulated. In this manuscript, we report the generation and characterization of antibodies towards each mouse granulin. With these unique antibodies, we have shown that [1] The levels of granulins A and B are differently regulated compared to the levels of granulins C, E and F [2]; Granulins B, C and E are heavily glycosylated and the glycosylation pattern is subject to regulation. Due to the redundancy and cross-regulation of lysosomal proteases, it is challenging to dissect the precise mechanisms involved in PGRN processing. Nevertheless, our results show that cathepsin B might play a role in regulating the levels of granulins A and B (Fig. 4a) and ablation of cathepsin D leads to decreased ratios of granulins A, B and C to PGRN (Fig. 4b) (Table S2). Ablation of PSAP results in a general reduction of PGRN processing, due to lysosomal trafficking defects. However, the fold of increase in the levels of granulins C and F is much higher than granulins A and B (Fig. 5b, Table S2), further supporting differential regulation of individual granulin peptides. In addition, we have shown that granulin A can be detected in the lysosome in both neurons and microglia and the levels of granulin A in microglia are regulated differently in response to different stimuli. In summary, the generation of antibodies specific to individual granulin peptides has yielded novel insights into the function of regulation granulins in the lysosome in physiological and pathological conditions.

Material and methods

Primary antibodies and reagents

The following antibodies were used in this study: mouse anti-GAPDH (Proteintech Group, 60,004–1-Ig), mouse anti-GFP (Proteintech Group), rat anti-mouse LAMP1 (BD Biosciences, 553,792), sheep anti-mouse PGRN (R&D Systems, AF2557) and rabbit anti IBA-1 (Wako, 01919741). Fluorescently labelled second antibodies were purchased from Li-Cor and Invitrogen.

The following reagents were also used in the study: Dulbecco’s modified Eagle’s media (DMEM) (Cellgro, 10–017-CV), 0.25% Trypsin (Corning, 25–053-CI), Papain (Worthington, LS003120), DNase I (Sigma D5025), Odyssey blocking buffer (LI-COR Biosciences, 927–40,000), Poly-D, L-ornithine (Sigma P0421), protease inhibitor (Roche, 05056489001), Pierce BCA Protein Assay Kit (Thermo scientific, 23,225) and O.C.T compound (Electron Microscopy Sciences, 62,550–01).

Cell culture

HEK293T were maintained in Dulbecco’s modified Eagle’s medium (Cellgro) supplemented with 10% fetal bovine serum (Gibco) and 1% Penicillin–Streptomycin (Invitrogen) in a humidified incubator at 37 °C and 5% CO2. Cells were transiently transfected with GFP tagged granulins using polyethyleneimine as described [21]. Cells were harvested 2 days after transfection using ice cold RIPA buffer (150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) with 1 mM PMSF, proteinase and phosphatase inhibitors.

WT and Grn−/− mouse primary cortical neurons and microglia were isolated from P0 to P2 pups according to published protocols [16, 37].

Mouse strains

C57/B16 mice and Grn−/− mice [38] were obtained from The Jackson Laboratory. Ctsd−/− [39], Ctsb−/− [40], Ctsl−/− [41], Ctsb−/− Ctsl−/− [33], Ctsk−/− [42] and Ctsz−/− [43] mice were characterized previously. PSAP knockout mice were previously described [44]. All animals (1–6 adult mice per cage) were housed in a 12 h light/dark cycle.

Stroke and demyelination induction

Rose Bengal was used to induce stroke using a modified protocol [45]. Briefly, 4 months old mice were injected retro-orbitally with Rose Bengal (50 μl, 10 mg/ml) followed by 5 min illumination of the intact skull with a 561 nm laser. The skin was then sutured and mice were treated with 0.1 mg/kg Buprenorphine every 8 h for 24 h after surgery. Mice were allowed to recover for 7 days before perfusion and tissue collection.

Demyelination was induced by supplementing the diet with 0.2% (w/w) cuprizone (bis [cyclohexanone]...
oxalidihydrazone) in powdered rodent chow [46]. 10-week-old mice were fed a cuprizone supplemented diet for 5 weeks, during which the rodent chow (5 g/mouse/day) was replaced every other day. Untreated control mice were fed normal crushed chow for 5 weeks.

**Tissue preparation and western blot analysis**

Mice were perfused with 1× PBS and tissues were dissected and snap-frozen with liquid nitrogen and kept at −80 °C. On the day of the experiment, frozen tissues were thawed and homogenized on ice with bead homogenizer (Moni International) in ice-cold RIPA buffer (150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) with 1 mM PMSF, proteinase and phosphatase inhibitors. After centrifugation at 14,000×g for 15 min at 4 °C, supernatants were collected. Protein concentrations were determined via BCA assay, then standardized. Equal amounts of protein were mixed with loading buffer with fresh b-mercaptoethanol. Samples were separated by 4–12% Bis-Tris PAGE (Invitrogen) and transferred to 0.2 μm nitrocellulose. Western blot analysis was performed as described [15]. To quantify the levels of full-length PGRN or each granulin peptide (GRN), Image J software was used to measure the density of protein bands (75 kDa or 10 kDa). These values were normalized to GAPDH. To compare the levels of granulin in different tissues, the levels of granulins were first normalized to GPADH and then normalized to the value of liver, lung or spinal cord samples in the same gel.

**De-glycosylation assay**

Spleen and/or liver lysates from WT mice were immunoprecipitated using anti-granulin B, C or E antibodies and the immunoprecipitates were treated with PNGase F (New England Biolabs) according to the manufacturer’s instructions.

**Immunofluorescence staining, image acquisition, and analysis**

Mice were perfused with PBS and then 4% paraformaldehyde (PFA). The brains were removed and continuously postfixed overnight in 4% PFA at 4 °C. After being dehydrated, coronal brain sections (20 μm) were cut using a cryostat (Leica, Heidelberg, Germany) and processed for immunostaining. For granulin A staining, brain sections from *Grn*−/− mice were first blocked and permeabilized with 0.1% saponin in Odyssey blocking buffer followed by incubation with our homemade rabbit anti-mouse GRN-A antibody overnight at 4 °C. The supernatants were then collected to be used as primary antibody solution in subsequent immunostaining using brain sections. Tissue sections were blocked and permeabilized with 0.1% saponin in Odyssey blocking buffer before incubating with primary antibodies overnight at 4 °C. The next day, sections were washed with PBS three times followed by incubation with secondary fluorescent antibodies and Hoechst at room temperature for 2 h. The slides were then mounted using a mounting medium (Vector laboratories). Images were acquired on a CSU-X spinning disc confocal microscope (Intelligent Imaging Innovations) with an HQ2 CCD camera (Photometrics) using 100x objectives, 10 to 15 different random images were captured from the cortex or the corpus callosum region.

For the quantitative analysis of PGRN and GRN-A levels in microglia, the IBA1+ microglia were selected using the region of interest (ROI) tool after the data channels were separated (Image\Color\Split Channels). Next, PGRN or GRN-A signals within the IBA1 ROI were selected (Analyzer\tools\ROI manager) and measured.

**Statistical analysis**

All statistical analyses were performed using GraphPad Prism 8. All data are presented as mean ± SEM. Statistical significance was assessed by unpaired two-tailed Student’s t-test (for two groups comparison) or one-way ANOVA tests with Bonferroni’s multiple comparisons (for multiple comparisons). *P* values less than or equal to 0.05 were considered statistically significant.

Abbreviations

FTLD: frontotemporal lobar degeneration; NCL: neuronal ceroid lipofuscinosis; PGRN: progranulin; PSAP: prosaposin; Cts: cathepsin

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13024-021-00513-9.

---

**Additional file 1: Figure S1.** HEK293T lysates and media containing GFP or GFP tagged mouse granulins were probed with sheep anti-mouse PGRN antibodies from R&D systems to detect each individual granulin peptide. Figure S2. Quantification of the levels of individual granulins and the ratio between granulins and PGRN in the spleen, lung and kidney lysates from 4 to 5 months old WT and *Grn*−/− mice. The value was normalized to that of liver sample on the same blot (set as 1). Data presented as mean ± SEM. n = 3, *, *P < 0.05*, **, *P < 0.01*, ***, *P < 0.001*, ****, *P < 0.0001*, unpaired two-tailed Student’s t-test. Figure S3. Analysis of PGRN and granulin levels in brain regions and spinal cord of female mice. (a) Western blot analysis of cortical and spinal cord lysates from 4 to 5 month old WT and *Grn*−/− mice with antibodies against full length of PGRN and individual granulin A and C as indicated. (b) Western blot analysis of tissue lysates from 4.5 to 5 months old female WT mice with antibodies against full length of PGRN and individual granulin A and C as indicated. CX = cortex, Hp = hippocampus, CC = corpus callosum, Tha = thalamus, Cb = cerebellum, BS = brain stem, SC = spinal cord. (c) Quantification of experiment in (a). The ratio between total granulins to full length PGRN was quantified and normalized to that of spinal cord. n = 3, 4. Data presented as mean ± SEM. Table S1. Sequences of mouse granulin peptides used in our study. Table S2. Summary in changes in PGRN levels and GRN/PGRN ratios in mice deficient in cathepsin or PSAP. n.s.c: No significant changes.
Acknowledgements
We thank Kenton Wu for proofreading the manuscript.

Authors’ contributions
T.Z. determined changes in granulins in various tissues lysates. X.W. purified all the recombinant GST-granulin proteins for immunization. M.N.S. characterized the specificity of granulin antibodies using overexpressed cell lysates. H.D. helped with mouse studies and tissue sample preparation. M.D.P. characterized the specificity of the sheep anti-PRGN antibody from R&D systems. L. J. T. and N. N. helped with Rose Begal stroke models. T. R. provided tissues from cathepsin knockout mice. F.H. supervised the project and wrote the manuscript together with T.Z. All authors have read and edited the manuscript. All author(s) read and approved the final manuscript.

Authors’ information
T.Z., H.D., TF., M.N.S., X.W., M.D.P. and F.H. are from the Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, USA. L. J. T. and N. N. are from Nancy E. and Peter C. Meining School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA. T.R. is from the Institute of Molecular Medicine and Cell Research, Medical Faculty and BIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany.

Funding
NINDS/NIA (RO1NS088484 & RO1NS095954) and the Bluefield project to cure frontotemporal dementia to F.H; Deutsche Forschungsgemeinschaft (DFG) NINDS/NIA (R01NS088448 & R01NS095954) and the Bluefield project to cure frontotemporal lobar degeneration. Hum Mol Genet. 2006;15(20):2988–3001. https://doi.org/10.1038/hmg/dd241.

Availability of data and materials
The data supporting the findings of this study are included in the supplemental material. Additional data are available from the corresponding author on request. No data are deposited in databases.

Declarations
Ethics approval and consent to participate
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. The work under animal protocol 2017–0056 is approved by the Institutional Animal Care and Use Committee at Cornell University.

Consent for publication
All authors have given consent for publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, 345 Weill Hall, Ithaca, NY 14853, USA. 2Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, USA. 3Institute of Molecular Medicine and Cell Research, Medical Faculty and BIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany.

Received: 8 November 2021 Accepted: 22 December 2021 Published online: 04 February 2022

References
1. Bateman A, Bennett HP. The granulin gene family: from cancer to dementia. Bioessays. 2009;31(11):1245–54. https://doi.org/10.1002/bies.200900086.
2. Cenic B, Septon CF, Kulkar Cenik B, Herz J, Yu G. Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem. 2012;287(39):32298–306. https://doi.org/10.1074/jbc.R112.399170.
3. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916–9. https://doi.org/10.1038/nature05016.
4. Cruts M, Gijselink I, van der Zee J, Engelborghs S, Wills H, Pincir D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442(7105):920–4. https://doi.org/10.1038/nature05017.
5. Gass J, Cannon A, Mackenzie IR, Roeve B, Baker M, Adamson J, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15(20):2988–3001. https://doi.org/10.1038/hmg/dd241.
6. Almeida MR, Macario MC, Ramos L, Baldeiras I, Ribeiro MH, Santana I. Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiol Aging. 2016;41:200.e1–5.
7. Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet. 2012;90(6):1102–7. https://doi.org/10.1016/j.ajhg.2012.04.021.
8. Kao AW, McKay A, Singh PP, Brunet A, Huang EJ. Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci. 2017;18(6):325–33. https://doi.org/10.1038/nrn.2017.36.
9. Paushder DH, Du H, Feng T, Hu F. The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathol. 2018;136(1):1–17. https://doi.org/10.1007/s00401-018-1861-8.
10. Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, et al. Accelerated lipofuscinosis and ubiquitinization in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol. 2010;177(1):23–4. https://doi.org/10.2353/ajpath.2010.090915.
11. Tanaka Y, Chambers JK, Matsuaki T, Yamanojou K, Nishiura M. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta Neuropathol Commun. 2014;2(1):78. https://doi.org/10.1186/s40478-014-0078-x.
12. Hu F, Padalkavadana T, Vaeger CB, Brady OA, Zheng Y, Mackenzie IR, et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron. 2010;69(4):654–67. https://doi.org/10.1016/j.neuron.2010.09.034.
13. Belcastro V, Siciliano V, Gregoretti F, Mithbaokar P, Dharmalingam G, Berlingeri S, et al. Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. Nucleic Acids Res. 2011;39(20):8677–80. https://doi.org/10.1093/nar/gkr593.
14. Sandielli M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473–7. https://doi.org/10.1126/science.1174447.
15. Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, et al. Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. J Cell Biol. 2015;210(6):991–1002. https://doi.org/10.1083/jcb.201502029.
16. Zhou X, Sun L, Bracco O, Choi JW, Jia Y, Nana AL, et al. Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations. Nat Commun. 2017;8(1):15277. https://doi.org/10.1038/s41467-017-01527-7.
17. Holler CJ, Taylor G, Deng Q, Kumar T. Intracellular proteolysis of progranulin generates stable, lysosomal granulins that are haploinsufficient in patients with frontotemporal dementia caused by GRN mutations. eNeuro. 2017;4(4). https://doi.org/10.1523/ENEURO.0100-17.2017.
18. Lee CW, Stankowski JN, Chew J, Cook CN, Lam YM, Almeida V, et al. The lysosomal protein cathepsin L is a progranulin protease. Mol Neurodegener. 2017;12(1):55. https://doi.org/10.1186/s13024-017-0205-9.
19. Zhou X, Paushder DH, Feng T, Sun L, Reinheckel T, Hu F. Lysosomal processing of progranulin. Mol Neurodegener. 2017;12(1):62. https://doi. org/10.1186/s13024-017-0205-9.
20. O’Brien JS, Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J. 1991;5(3):301–8. https://doi.org/10.1096/fasebj.5.3.1991879.
21. Zhou X, Paushder DH, Feng T, Pardon CM, Mendoza CS, Hu F. Regulation of cathepsin D activity by the FTLD protein progranulin. Acta Neuropathol. 2017;134(1):1–3. https://doi.org/10.1007/s00401-017-1719-5.
22. Valdez C, Wong YC, Schwake M, Bu G, Wzrecki ZK, Kricinski D. Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. Hum Mol Genet. 2017;26(24):4861–72. https://doi.org/10.1093/hmg/ddx364.
23. Beel S, Moissee M, Damme M, De Muynck L, Robberecht W, Van Den Bosch L, et al. Progranulin functions as a cathepsin D chaperone to stimulate
axonal outgrowth in vivo. Hum Mol Genet. 2017;26(15):2850–63. https://doi.org/10.1093/hmg/ddx162.
24. Butler VJ, Cortopassi WA, Argouarch AR, Ivry SL, Craik CS, Jacobson MP, et al. Progranulin stimulates the in vitro maturation of pro-Cathepsin D at acidic pH. J Mol Biol. 2019;431(5):1038–47. https://doi.org/10.1016/j.jmb.2019.01.027.
25. Arrant AE, Roth JR, Boyle NR, Kashyap SN, Hoffmann MQ, Murchison CF, et al. Impaired beta-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations. Acta Neuropathol Commun. 2019;7(1):218. https://doi.org/10.1186/s40478-019-0872-6.
26. Valdez C, Ysselstein D, Young TJ, Zheng J, Knaic D. Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Hum Mol Genet. 2019;28(5):716–26. https://doi.org/10.1093/hmg/ddz229.
27. Zhou X, Paushert D, Pagan MD, Kim D, Nunez Santos M, Lieberman RL, et al. Progranulin deficiency leads to reduced glucocerebrosidase activity. PLoS One. 2019;14(7):e0212382. https://doi.org/10.1371/journal.pone.0212382.
28. Songrirote K, Li Z, Ashford D, Bateman A, Thomas-Oates J. Development role of progranulin in regulating amyloid-beta dynamics and responses. Life Sci Alliance. 2021;4(7):e202000874. https://doi.org/10.26508/lsa.202000874.
29. West CM. Current ideas on the significance of protein glycosylation. Mol Biol Cell. 1986;7(2):23–20. https://doi.org/10.1091/0F0230632.
30. Petkau TL, Neale SJ, Paushter DH, Pagan MD, Kim D, Nunez Santos M, Lieberman RL, et al. Progranulin deficiency leads to reduced glucocerebrosidase activity. PLoS One. 2019;14(7):e0212382. https://doi.org/10.1371/journal.pone.0212382.
31. Matsuzaki T, Asakura R, Suzuki M, Yamanouchi K, Nishihara M. Age-related phenotypes and application of mass spectrometric methods for the analysis of progranulin N-glycosylation. J Proteome. 2010;72(8):1479–90. https://doi.org/10.1016/j.jprot.2010.02.013.
32. Gotzli JK, Mori K, Darmme M, Fellerer K, Tahirovic S, Kleinberger G, et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol. 2014;127(6):845–60. https://doi.org/10.1007/s00401-014-1262-6.
33. Sevenich L, Pennacchio LA, Peters C, Reinheckel T. Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice. Mol Biol Chem. 2006;387(7):885–91. https://doi.org/10.10151/8C2.006.1015.
34. Felibou U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT, et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A. 2002;99(12):7883–8. https://doi.org/10.1073/pnas.99.12.7883.
35. Martinez-Fabregas J, Prescott A, van Kasteren S, Pedrioli DL, McLean I, Moles A, et al. Lysosomal protease deficiency or substrate overload induces an oxidative-stress mediated STAT3-dependent pathway of lysosomal homeostasis. Nat Commun. 2018;9(1):1534. https://doi.org/10.1038/s41467-018-07741-6.
36. Tyunela J, Palmer DN, Raumann M, Haltia M. Storage of saposins a and D in infantile neuronal ceroid-lipofuscinosis. FEMS Lett. 1993;330(1):8–12. https://doi.org/10.1016/0168-9539(93)00808-D.
37. Du H, Wong MY, Zhang T, Santos MN, Hsu C, Zhang J, et al. A multifaceted role of progranulin in regulating amyloid-beta dynamics and responses. Life Sci Alliance. 2021;4(7):20000874. https://doi.org/10.26508/fsa.20000874.
38. Yin F, Barerge R, Thomas B, Zhou P, Qian L, Jia T, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207(1):117–28. https://doi.org/10.1084/jem.20091568.
39. Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, et al. Mouse deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 1995;14(15):3599–608. https://doi.org/10.1093/EMBOJ.14.15.3599.tb0029x.
40. Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenburger M, Reinheckel T, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest. 2000;106(6):773–81. https://doi.org/10.1172/JCI10934.
41. Roth W, Deussing J, Botchkarev VA, Pauly-Evers M, Saftig P, Hafner A, et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and perturbation of hair follicle cycling. FASEB J. 2000;14(13):2075–86. https://doi.org/10.1096/fj.99-0970com.
42. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95(23):13453–8. https://doi.org/10.1073/pnas.95.23.13453.
43. Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Muller S, et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A. 2010;107(8):497–502. https://doi.org/10.1073/pnas.090724.0107.
44. Fujita N, Suzuki K, Vanier MT, Popko B, Maeda N, Klein A, et al. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet. 1996;5(6):711–25. https://doi.org/10.1002/hmg.16705.6.711.
45. Llorea G, Pinkham K, Liesz A. Modeling stroke in mice: focal cortical lesions by Photothrombosis. J Vis Exp. 2021;17(1). https://doi.org/10.3791/62536.
46. Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJ. Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol. 2003;13(3):329–39. https://doi.org/10.1111/j.1750-3639.2003.tb00332.x.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions